Dr. Osborne Discusses the Future of Treatment in HER2+ Breast Cancer

C. Kent Osborne, MD
Published Online: Thursday, Mar 16, 2017



C. Kent Osborne, MD, director, Dan L. Duncan Comprehensive Cancer Center, Baylor College of Medicine, discusses the death of chemotherapy and rise of targeted agents in the treatment of patients with HER2-positive breast cancer.

The era of chemotherapy in HER2-positive breast cancer has ended, says Osborne, as genomic medicine that targets specific abnormalities within tumors is showing great effect.

According to Osborne, targeting the driver and alternate escape pathways of these tumors is next on the agenda for these agents.

<<< View more from the St. Gallen's Breast Cancer Conference


C. Kent Osborne, MD, director, Dan L. Duncan Comprehensive Cancer Center, Baylor College of Medicine, discusses the death of chemotherapy and rise of targeted agents in the treatment of patients with HER2-positive breast cancer.

The era of chemotherapy in HER2-positive breast cancer has ended, says Osborne, as genomic medicine that targets specific abnormalities within tumors is showing great effect.

According to Osborne, targeting the driver and alternate escape pathways of these tumors is next on the agenda for these agents.

<<< View more from the St. Gallen's Breast Cancer Conference



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Medical Crossfire®: Leveraging New Evidence in the Context of Evolving Early-Stage Treatment Standards in HER2-Positive Breast CancerJan 30, 20181.5
14th Annual School of Breast Oncology® OnlineFeb 10, 201825
Publication Bottom Border
Border Publication
x